Signet Therapeutics and XtalPi: AI + Organoid Gastric Cancer Targeted Drug SIGX1094 Moves Toward Key Clinical Validation
The first-in-class targeted drug for diffuse gastric cancer worldwide, SIGX1094, jointly developed by Signet Therapeutics and XtalPi, has essentially completed Phase I clinical trials and has received both FDA Orphan Drug and Fast Track designations, with the potential to reach the market after completing Phase II clinical trials. This molecule was the candidate found when the AI + organoid approach had synthesized the 94th molecule; the second pipeline asset, the pan-TEAD inhibitor SIGX2649, has received dual IND approvals from China and the U.S. and is expected to begin clinical trials in November.
#Industry news#English text is being prepared.